Appendix D

Detailed Structure of the study database

Card Name	Short Name	Position	Field Name	Short Name	Number	Type	
Study description	DESCR	1					
			Study title	TITLE	8	Character	(15)
			Full study title	FTITLE	9	Character	(50)
			Study sex	sSEX	10	Graded	(system 15)
			Lowest age in study	sAGELO	58	Measured+v	(0 to 18)
			Highest age in study (at baseline)	sAGEHI	59	Measured+v	(0 to 21)
			Highest age in study at final followup	sAGEHF	60	Measured	(0 to 25)
			Study race	sRACE	11	Graded	(system 16)
			Continent	CONT	12	Graded	(system 17)
			Country in N America	NAMER	14	Graded	(system 18)
			US state	USSTAT	15	Graded	(system 19)
			Country in S/C America	SCAMER	16	Graded>0	(system 21)
			Country in W Europe	WEUR	17	Graded	(system 22)
			Country in E Europe/Balkans	EEUR	18	Graded	(system 23)
			Country in Asia	ASIA	20	Graded	(system 25)
			Country in Australasia	AUSLIA	21	Graded	(system 27)
			Country in Africa	AFRICA	22	Graded	(system 31)
			Location within country	LOCAT	61	Character	(50)
			Start year of study	BEGYR	23	Measured	(1900 to 2002)
			End year of study	ENDYR	24	Measured	(1900 to 2002)
			Final follow up year	FINFYR	25	Measured	(1900 to 2002)
			Principal publication year	PUBYR	26	Measured	(1900 to 2002)
			Reference ID of principal publication	REFID	27	Character	(12)
			Reference ID of additional publication(s)	ADDREF	48	Character	(50)
			Overlap{ OVERLAP}	OVERL	57	Graded>0	(system 48)
			Principal/subsidiary study	PRINC	99	Graded>0	(system 51)
			REF group	REFGP	127	Character	(6)
Study design	DESIGN	2					
			Study type	STYPE	33	Graded	(system 28)
			Type of controls (for CC studies)	CONTRL	34	Graded	(system 29)
			Control diseases/cause of death	CONDIS	35	Character	(50)
			Type of population	POPUL	36	Graded	(system 42)
			Medical exclusions	MEDEXC	91	Character	(50)
			Other exclusions	OTHEXC	92	Character	(50)
			Type of population - controls (if diff from cases)	POPCON	72	Graded	(system 50)
			Respondent	RESPON	38	Graded	(system 44)
			Child smokes	CHISMO	63	Graded>0	(system 49)
			Standard questionnaire	QUEST	125	Graded	(system 54)
Asthma	ASTHMA	3					
			Lifetime/incidence/unspec asthma available	LIFAST	103	Presence	(system 6)
			Source of lifetime asthma diagnosis	DIAGLS	104	Graded	(system 43)
			Timing of lifetime asthma	TIMLAS	105	Graded>0	(system 52)
			Timing of incidence asthma	INCAST	126	Graded>0	(system 55)
			Description of lifetime asthma	DESLAS	106	Character	(50)
			Current asthma available	CURAST	107	Presence	(system 6)
			Current asthma is first occurrence	FIRAST	108	Presence	(system 6)
			Repeat measures for current asthma	REPCAS	109	Presence	(system 6)
			Source of current asthma diagnosis	DIAGCS	110	Graded	(system 43)
			Timing of current asthma	TIMCAS	111	Graded>0	(system 53)
			Description of current asthma	DESCAS	112	Character	(50)
			Number of lifetime asthma cases	NLAST	113	Measured	(0 to 32765)
			Number of current asthma cases	NCAST	114	Measured	(0 to 32765)
			Total number of subjects	NTOT	115	Measured	(0 to 999999)
Matching factors	MATCH	4					
			Cases and controls matched on sex	MATSEX	76	Presence	(system 6)
			Cases and controls matched on age (CC)	MATAGE	77	Presence	(system 6)
			Cases and controls matched on race	MATRAC	78	Presence	(system 6)
			Matched on location (within study area)	MATLOC	79	Presence	(system 6)
			Cases and controls matched on socioeconomic status	MATSES	80	Presence	(system 6)
			Matched on hospital admission (ward, date etc)	MATHOS	124	Presence	(system 6)

Confounders considered CONFND 5				
Total number of adjustment factors used	TOTCO	44	Measured	(0 to 99)
Adjusted for sex	COSEX	45	Presence	(system 6)
Adjusted for age	COAGE	46	Measured	(0 to 10)
Adjusted for race	CORACE	47	Measured	(0 to 10)
Adjusted for location within study	COLOC	65	Measured	(0 to 10)
Adjusted for type of respondent	CORESP	83	Measured	(0 to 10)
Adjusted for interview setting	COIVST	86	Measured	(0 to 10)
Adjusted for year of diagnosis	COYRDG	121	Measured	(0 to 10)
Adjusted for family (parent/sibl) medical history	COFMED	66	Measured	(0 to 10)
Adjusted for parent's age	COPAGE	93	Measured	(0 to 10)
Adjusted for SES (inc parental education)	COSES	67	Measured	(0 to 10)
Adjusted for household composition	COHOCO	68	Measured	(0 to 10)
Adjusted for day care	CODAYC	95	Measured	(0 to 10)
Adjusted for air conditioning/humidifier	COAIRC	69	Measured	(0 to 10)
Adjusted for cooking/heating methods	COCOHE	90	Measured	(0 to 10)
Adjusted for damp/mould in home	CODAMP	94	Measured	(0 to 10)
Adjusted for housing quality/age/size	COHOUS	117	Measured	(0 to 10)
Adjusted for pets in household	COPETS	88	Measured	(0 to 10)
Adjusted for exposure to food/housedust allergens	COALGN	89	Measured	(0 to 10)
Adjusted for farming	COFARM	96	Measured	(0 to 10)
Adjusted for religion	CORELI	97	Measured	(0 to 10)
Adjusted for mobility (par/ch brn abrd, moved hous	COMOB	120	Measured	(0 to 10)
Adjusted for child other medical history/symptoms	COCMED	87	Measured	(0 to 10)
Adjusted for obesity/BMI	COOBES	70	Measured	(0 to 10)
Adjusted for exercise	COEXER	122	Measured	(0 to 10)
Adjusted for diet/alcohol	CODIET	123	Measured	(0 to 10)
Adjusted for child active smoking	COCHSM	71	Measured	(0 to 10)
Adjusted for maternal smoking in pregnancy	COMSMP	84	Measured	(0 to 10)
Adjusted for parental smoking current/since birth	COPSMC	85	Measured	(0 to 10)
Adjusted for household ETS exposure	COHSM	118	Measured	(0 to 10)
Other confounders considered but rejected	COREJE	119	Presence	(system 6)
Other results (not current db) OTHRES 6				
Other definitions of asthma available	OTHAST	53	Presence	(system 6)
Wheezing/wheezing bronchitis available	WHEEZE	54	Presence	(system 6)
Other exposures available	OTHEXP	55	Presence	(system 6)
Other results for child smokers available	OTHCSM	64	Presence	(system 6)
Results by other stratifying factors available	OTHSTR	82	Presence	(system 6)
Derived 1 - RRs available DER1 7				
Number of RRs	NRRS	131	Measured	(0 to 100)
Parental exposure RRs	EXPAR	132	Measured	(0 to 100)
Parental passive smoking exposure RRs	EXPARP	133	Measured	(0 to 100)
Household exposure RRs	EXHH	134	Measured	(0 to 100)
Total exposure RRs	EXTOT	135	Measured	(0 to 100)
Biochemical exposure RRs	EXBIOC	137	Measured	(0 to 100)
In utero x parent exposure combination RRs	EXUTP	138	Measured	(0 to 100)
In utero x household combination exposure RRs	EXUTHH	139	Measured	(0 to 100)
In utero x biochemical combination exposure RRs	EXUTBI	140	Measured	(0 to 100)

The grading systems used are as follows

Grading System	Level	(character equivalent)	Tumour Type
6	1	(x) present	0
15	1	(b) both	0
	2	(m) male	0
	3	(f) female	0
16	1	(a) all (in country)	0
	2	(w) whites (inc hispanic)	0
	3	(b) blacks	0
	4	(4) whites and blacks	0
	5	(5) whites excluding hispanics	0
	6	(c) chinese	0
	7	(j) japanese	0
	8	(8) fijians and indians	0
17	1	(1) NAmerica	0
	2	(2) SCAmerica	0
	3	(3) WEurope/Scandinavia	0
	4	(4) EEurope/Balkans	0
	5	(5) Asia	0
	6	(6) Australasia	0
	7	(7) Africa	0
18	1	(1) USA	0
	2	(2) Canada	0
	3	(3) USA and Canada	0
19	1	(1) all	0
	2	(2) Cal,Wash,Oreg	0
	3	(3) Mont,Id,Wyo	0
	4	(4) Nev,Ut,Ariz	0
	5	(5) Colo,NMex	0
	6	(6) NDak,SDak,Neb	0
	7	(7) Kan,Okla	0
	8	(8) Tex	0
	9	(9) Minn,Ia,Wis,Ill,Mo	0
	10	(t) Ark,Miss,La,Al	0
	11	(a) Mich,Ind,Oh,Tenn	0
	12	(b) Fla,Ga,SC,NC	0
	13	(c) Pa,NJ,Md,WVa,Va,Del,WashDC	0
	14	(d) Vt,Me,NY,NH,Mass,RI,Conn	0
	15	(e) Ak	0
	16	(f) Hi	0
	17	(g) multi (not all)	0
21	1	(1) Costa Rica	0
	2	(2) Brazil	0
	3	(3) Mexico	0
22	1	(1) UK	0
	2	(2) Ireland	0
	3	(3) Denmark	0
	4	(4) Norway	0
	5	(5) Sweden	0
	6	(6) Finland	0
	7	(7) Iceland	0
	8	(8) Spain	0
	9	(9) Portugal	0
	10	(t) France	0
	11	(a) Belgium	0
	12	(b) Netherlands	0
	13	(c) Luxembourg	0
	14	(d) Switzerland	0
	15	(e) Germany	0
	16	(f) Austria	0
	17	(g) Italy	0
	18	(h) Malta	0
	19	(i) Multi	0

23	1	(1) Czechoslovakia etc	0
	2	(2) Greece	0
	3	(3) Hungary	0
	4	(4) Poland	0
	5	(5) Turkey	0
	6	(6) Russia	0
25	1	(1) Japan	0
	2	(2) China	0
	3	(3) HongKong	0
	4	(4) Malaysia	0
	5	(5) India	0
	6	(6) Nepal	0
	7	(7) Saudi Arabia	0
	8	(8) UAE	0
	9	(9) Taiwan	0
	10	(t) Israel	0
	11	(a) Sri Lanka	0
	12	(c) Korea	0
27	1	(1) Australia	0
	2	(2) New Zealand	0
	3	(3) Fiji	0
28	1	(c) case/control	0
	2	(p) prospective	0
	3	(x) cross-sectional	0
29	1	(1) healthy	0
	2	(2) diseased/hospital	0
	3	(3) healthy + diseased	0
	4	(4) unstated	0
	5	(5) decedents	0
	6	(6) healthy + decedents	0
	7	(7) diseased + decedents	0
	8	(8) subcohort	0
31	1	(1) Ghana	0
	2	(2) Kenya	0
	3	(3) Nigeria	0
	4	(4) South Africa	0
42	1	(1) all children	0
	2	(2) random children	0
	3	(3) all schoolchildren	0
	4	(4) random schoolchildren	0
	5	(5) all in given school(s)	0
	6	(6) random in given school(s)	0
	7	(7) all hosp/clinic patients	0
	8	(8) random hosp/clinic patients	0
	9	(9) all in given hosp/clinic(s)	0
	10	(a) random in given hosp/clinic(s)	0
	11	(b) all primary care patients	0
	12	(c) random primary care patients	0
	13	(d) all at given primary care(s)	0
	14	(e) random at given prim care(s)	0
	15	(f) school NOS	0
	16	(g) primary care NOS	0
	17	(h) all gvn hosp high allergy risk	0
	18	(i) all fam newborn deliv gvn hosp	0
	19	(j) rndm in gvn school(s) athletes	0
	20	(k) all schlch living on farms	0
	21	(l) all prim care & born same hosp	0
	22	(m) all preterm infts brn gvn hosp	0
	23	(n) all children rndm households	0
	24	(o) all newborns at given hosp(s)	0
	25	(p) all twins born same country	0
	26	(q) all preschool routine hlth chk	0
	27	(r) rnd newborns gvn hosp(s)	0
	28	(s) all chld all asthmatic famlies	0
	29	(t) all travellers + all gvn schl	0
	30	(u) unspecified	0
	31	(v) rndm newborns high SIDS risk	0
	32	(w) hospital NOS	0
	33	(x) all gvn prim cr high algy risk	0
	34	(y) all chld rndm parent NCDS	0
	35	(z) bronchiolitis gvn hosp+pop con	0

43	1	(1) Medical records	0
	2	(2) Parent report (physician diag)	0
	3	(3) Parent report (other/uns/mix)	0
	4	(4) Child report (physician diag)	0
	5	(5) Child report (other/uns/mix)	0
	6	(6) Med rec or par rep (phys diag)	0
	7	(7) Parent or child rep (phys dg)	0
	8	(8) Parent or child rep (oth/unsp)	0
	9	(9) Unspecified	0
	10	(a) Med rec or par rep (oth/unsp)	0
44	1	(c) Child	0
	2	(p) Parent	0
	3	(m) Medical records	0
	4	(b) Parent and child	0
	5	(u) Unspec (parent/child)	0
	6	(h) Household member	0
	7	(7) Accompanying adult	0
	8	(8) Parent or child (dep age)	0
48	1	(1) none	0
	2	(2) MCCON1/GILLIL	0
	3	(3) FARBE1/FARBE2/FARBE3	0
	4	(4) MELIA/SOMERV/CHINN	0
	5	(5) KELLY/BRABIN	0
	6	(6) HJERN1/HJERN2	0
	7	(7) STERN1/STERN2	0
	8	(8) KUEHR/SPIEKE	0
	9	(9) FORSB3/WILLE2	0
	10	(a) ALFRA1/ALFRA2	0
	11	(b) GOREN1/GOREN3/4/5/6	0
	12	(c) WOLFO1/WOLFO2/WOLFO3	0
49	1	(1) No mention	0
	2	(2) Smokers excl biochemically	0
	3	(3) Smokers excl questionnaire	0
	4	(4) Smokers excl unspecified	0
	5	(5) Smokers incl but few (bio/qu)	0
	6	(6) Smokers incl and adjusted for	0
	7	(7) No smokers found (bio/quest)	0
	8	(8) Assumed no smokers	0
	9	(9) Smokers included	0
	11	(b) Smkrs above given age excluded	0
	12	(c) No smkrs found above gvn age	0
	13	(d) Discussed, but no data avail	0
	14	(e) Smkrs inc as not signif univar	0
	15	(f) Smkrs inc, adj reje as not sig	0
	16	(g) Biochem excl discussd not used	0
	17	(h) No mention anal (but in quest)	0
	18	(i) No smokers NOS	0
50	1	(1) no chest/resp symptoms	0
	2	(2) all at given school(s)	0
	3	(3) no siblings with allergic dis	0
	4	(4) all newborns	0
	5	(5) no atopy	0
	6	(6) rndm from hosp catchment area	0
	7	(7) rndm at gvn schls no resp symp	0
	8	(8) no resp symptms or hist asthma	0
	9	(9) no signs of sensitisation	0
	10	(a) rndm hosp catchment no hist as	0
	11	(b) rndm schlch no asthma medicatn	0
	12	(c) no history recurrent wheeze	0
	13	(d) no TB, congen chest/heart prob	0
	14	(e) no history asthma	0
51	1	(1) Principal	0
	2	(2) Subsidiary	0

52	1	(1) Lifetime	0
	2	(2) NA (incidence only)	0
	3	(3) from age 1	0
	4	(4) unspecified	0
	5	(5) from age 2	0
	6	(6) from age 3	0
	7	(7) up to baseline	0
53	1	(1) current diagnosis	0
	2	(2) last n months (n<6)	0
	3	(3) last n months (6<=n<12)	0
	4	(4) last n months (12<=n<24)	0
	5	(5) last n years (2<=n<5)	0
	6	(6) current NOS	0
	7	(7) since baseline	0
54	1	(1) Non std/NA/NK	0
	2	(2) ISAAC	0
	3	(3) ATS/NHLI/ESP	0
	4	(4) MRC	0
	5	(5) IUATLD	0
	8	(8) WHO	0
	9	(9) ICHPPC	0
55	1	(1) since baseline (earlier excl)	0
	2	(2) lifetime (recruit at birth)	0
	3	(3) lifetime (retrospective)	0
	4	(4) NA (prevalence analysis only)	0